This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $809,614 to develop broadly neutralizing human monoclonal antibodies (BnAbs) against henipaviruses, a class of highly pathogenic viruses causing severe respiratory and neurological diseases. The primary objectives are to design novel immunogens that can elicit BnAbs against the henipavirus fusion (F) and...
The Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $959,792 to the Scripps Research Institute to develop a novel live-attenuated vaccine platform for Lassa fever. The research aims to create a safe and highly protective Lassa fever vaccine candidate, called RLASV/IGR-CD, that exhibits enhanced safety features and unbreachable attenuation. Key objectives...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under CFDA Program 93.859 Biomedical Research and Research Training, provides $757,299 to Abbratech Inc. to develop a comprehensive platform for identifying and validating recombinant antibodies specific to protein isoform splice-junction sites. The key products and services to be delivered under this "Directed Discovery and Validation of Anti-Splice-Junction Site Antibodies" project include: 1)...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Abwiz Bio Inc. a $561,538 Phase I Small Business Technology Transfer (STTR) grant under CFDA 93.855 - Allergy and Infectious Diseases Research. The grant will fund the development of neutralizing antibodies against Machupo virus, a New World arenavirus, using a stabilized-trimer immunogen. The goal is to identify and characterize antibodies that target multiple epitopes on the virus surface glycoprotein, which could lead...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $142,908 to the San Diego Biomedical Research Institute to conduct research on how antibody glycosylation influences natural killer (NK) cell activation and antibody-dependent cellular cytotoxicity (ADCC) during HIV infection. The key objectives are to: 1) Determine how monoclonal antibody glycosylation profiles affect signaling protein...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $240,300 to the Regents of the University of Michigan to develop bispecific antibodies (BABs) capable of efficiently penetrating the blood-brain barrier and delivering neutralizing antibodies against Eastern Equine Encephalitis Virus (EEEV) to the brain. The key objectives are to evaluate the brain uptake and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $683,927 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Icahn School of Medicine at Mount Sinai (ISMMS) to develop and characterize broadly neutralizing human monoclonal antibodies (mAbs) as potential therapeutics to inhibit human cytomegalovirus (CMV) infection and dissemination. The key objectives of this 1-year project are to: 1) identify neutralizing CMV mAbs targeting...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $741,917 to West Virginia University Research Corporation to develop therapeutic antibodies for the treatment of multidrug-resistant Pseudomonas aeruginosa infections, with a focus on sepsis. The key objectives are to characterize the mechanism of action of a lead antibody candidate, formulate it into a multivalent...
This $2 million cooperative agreement from the National Science Foundation will support Protabit LLC in developing artificial intelligence-enabled antibody engineering approaches to generate neutralizing antibodies against SARS-CoV-2. Funded through Jul 2022 to Jun 2024 under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the project aims to discover a large array of high-affinity neutralizing antibodies targeting multiple regions of the SARS-CoV-2 spike protein. This...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $843,620 to Albert Einstein College of Medicine to develop broadly protective human monoclonal antibody therapies against alphaviruses. The key goals are to: 1) engineer Fc mutations to enhance the in vitro and in vivo properties of broadly neutralizing antibodies, 2) perform viral escape studies to define mechanisms...